aceutical (Group) Co., Ltd.*

INTERIM REPORT 2020


Our Vision



Our Mission




Contents



Corporate



Directors



Corporate

Stock Abbreviation



Share Listing

A Share Registrar and Transfer Office in the PRC

H Share Registrar and Transfer Office in Hong Kong

```
J i - J i J j i i 183 . ' ■ ■ i i
```

Company's Website

Financial


1 11 1 1

Six months ended 30 June

	2020	2019
	RMB million	В лп
Operating results		
	13,965	14,085
į	7,749	8,486
🍗 👼 T. , if	1,292	1,490
	2,302	2,196
	1,715	1,516
B DA L LL	3,566	3,483
Profitability		
□ l	55.49%	60.25%
` → ■ 1.	9.25%	10.58%
	13.67%	12.92%



FINANCIAL REVIEW



REVENUE



D_I . _ | M A M _ I

SELLING AND DISTRIBUTION EXPENSES

R&D EXPENSES AND R&D EXPENDITURE

D. J. N. J. J. N. J. S. D. J. N. S. B1,689 H.J. N. J. J. S. 25.02% J. N. J. J. J. S. J. S. S. J. J. S. J. J. S. J. J. S. J. J. S. J. S. J. S. J. J. S. J. S.

SHARE OF PROFITS OF ASSOCIATES

D. _i, _n _i, _n _n _n _i _n _

PROFIT FOR THE PERIOD

ר בו 1910 ₪ , . בו , ה בו , ה בו , ה בו , ה בו 1,820 ₪ , . בו , ה בו ,

PROFIT FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

Total Debts



D_I . _I 📓 A 📓 _I

Maturity Structure of Outstanding Debts

	اً: ال	. С. : В
	30 June 2020	31 D 2019
្នុក 1 🖩	12,405	8,560
1	7,834 2,633 483	6,860 5,396 321
<u>,</u> ●	23,358	21,137

Available Facilities

A \$\int_{30}\$. 2020, \$\text{ \$\text{\$

Collateral and Pledged Assets

Cash Flow

	С. : В	
January – June	بر 🔹 🖳	
2020	2019	

		2013
ً ◙ ١١	1,461	1,450
المال المالية	(2,379)	(1,079)
, ■ U ·	827	(496)
	(91)	(125)
Canua au 'la aiu 'l' iu a	8,284	7,175
Com u o o o o o o o o o o o o o o o o o o	8,177	7,052

Management D_I . _I A A _I

D. J., n J., L., n n	0.85% i	B13,965	B1,359
D. J., n , J., n	. a n i a	B9,894 ม.เ โ , .	■
D , L , L , E E II		™ i: π⊓	С. : В
Business segment	Revenue Jan – Jun 2020	نمر هم	_l
j □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	9,952 2,639 1,359	10,814 1,793 1,459	7.97 47.18 6.85
D. J. (n J. J. (n J. J. (n J. J. J. (n J.	i	, 18 1	
		الأا با الاالأا الاالا أ الاا	2.6 L
D10 _111 _1 _1 _1 _1 _1 _1 _1 _1 _1 _1 _1 _1	n _ı n⊠ 2019.	2020 a . i i	В1,461 ц.,
DI	. n)	B1,689 i i 2019.

ا الله الآ ق C. : B

D_I. _| \(\begin{array}{c|cccc} A & \begin{

B1,116 B1,115 B1,115 B1,115 B1,115 B1,116 B1,115 B1,116 B1,115 B1,116 B1,115 B1,116 B1,115 B1,115 B1,116 B1,116 B1,115 B1,116 B1,115 B	.i , 19, .i , 335 .n
	n i m, (_ı ı mi 100

الها . وا ، أل ، أل الله والله . أله و ، أله و

Pharmaceutical manufacturing and R&D	Jan – Jun 2020	2019 (1)	j (%) U ■ ■ T I = I
) الاستعار : الاستعاد الاست الاستعاد الاستعاد الاستعاد الاستعاد الاستعاد الاستعاد الاستعاد ا	2) 1,767	1,807	2.19
	422	264	59.94
	1,800	2,331	22.77
	755	1,224	38.35
aj . a la . a l la a (6)	1,248	1,140	9.49
	247	419	41.03
■ A ■ L L M L L ()	452	675	32.97

D_I . _ | A A _ |

- 6: \square_{0} . \square

Management D_i . _i A A _i

No.	Name of R&D project on drugs (products)	R&D stages as a the Reporting Per			stages as at the o ting Period in oth St	
		R&D stage	clinical trial	R&D stage	tri	al
	_A, -189 (,	G J J M	∪ <u>M</u>	a a _1	ill a la U	⊻ي ۱ ٍ ا
	, C -411 , -1501	i C	∪ ⊠	Cıllı 🎽	n	■ (_i _n <u>_</u>
	, C -437 C -159 1001 (1)	C 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	∪ <u>⊠</u>	Çı		ر آ دکا نا
	,C -159 1001 (1) D	C-1-120	∪ <u>⊠</u> ∪ <u>⊠</u>	C'_1_1 📓 📮	n	ً گي ۱ ٍ ∟ آ
0	.jl , C -647 C■ . ı	A LILIM M				
1	C -207	A BLL! L! A		A (<u>ك</u> ل _أ ا_)	1 1 <u>1</u> 1	
	•			(ـــــــــــــــــــــــــــــــــــــ		
	1: _ n n⊠	n , M D v	. ⊠ n.⊠,			
	1: _ n n			DA;		
		. n ., n a a	ru⊃r ∰ Marri	DA; ⊠_⊔⊠ .		
A ⊠ ì	2: A a n a i' n n i i'. i l i i.	. n n	R8	DA; Solution Date of the corting Period	R&D sta e countries a	ages in other as at the end of orting Period Stage of
i 📓	2: A lin	. n n	R8	DA; Li	R&D sta e countries a the Rep	as at the end o
i 0. `	2: A lin	of R&D project on drugs	R&D stage	DA; BLID Stages in sat the end of the corting Period Stage of clinical tria	R&D stage R&D stage	as at the end o orting Period Stage of clinical tria
□ i	2: A lin	of R&D project on drugs	R8 China as Rep	DA; BD stages in sat the end of the corting Period Stage of clinical tria	R&D stage R&D stage	as at the end o orting Period Stage of clinical tria
□ 1	2: A lin	of R&D project on drugs cts)	R&China as Rep R&D stage	DA; BD stages in sat the end of the corting Period Stage of clinical tria	R&D sta e countries a the Rep	as at the end o orting Period Stage of clinical tria
© i	2: A lin	of R&D project on drugs cts)	R&China as Rep R&D stage	DA; But and a second and a sec	R&D stage R &D stage	as at the end o orting Period Stage of clinical tria

Management D_I . _I A A _I

No.	Туре	Name of R&D project on drugs (products)	China as at	stages in the end of the ing Period Stage of	countries as	es in other at the end of ting Period Stage of
			R&D stage	clinical trial	R&D stage	clinical trial
6	B_I _I <u>™</u>	L	A ' _ 3			
7	B_i _i <u>1</u>		GIIB 💆	∩ ⊠		
8	B_i _i <u>1</u> ⊠	ان اد A ا ا ان اد A ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا	A			
9	B_i _i ī⊠	i	A	_ ,		
10	B ₋₁ ∩⊠ ⊠	ا- الله الله الله الله الله الله الله ال	Cı_ı_ı 📓 🕍	n ⊠ (4))	
11	B_I ∩ ■	L	A			
	B_			∩ ⊠	A	
	B_I NM MIM		Cııı⊠ , ∭) Cııı⊠ , ∭	n⊠ /	A I LI A A	
	B. ∪		(¹ 7)		C	∩⊠
16	B. N⊠ ⊠	'	C	ΛM	(')	
17		. L L L A ■ 1 L L L L L L L L L L L L L L L L L L	Cı_ı_ı 📓 🕍	∩Mi		
18	B_	, K 56 , ⊠ A _ J _j _ J	A '_I_I			
19	C _1	C	Ci_i_i	∩⊠		
		,				

Management D_I . _I A A _I

Name of R&D project on drugs Chi No. Type (products)		China as at	R&D stages in China as at the end of the Reporting Period Stage of		ges in other s at the end of rting Period Stage of
		R&D stage	clinical trial	R&D stage	clinical trial
20 C	C	A ' - I - I M			
21 C .ı 2 .ı	C 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		∩ ⊠		
22 C _1 █ _1 i i i i		G_1_1	∩⊠	C	Λ⊠
23 C)	C _ l _ l 📓 🙀	∩⊠		
24 C _1 █ _1 i i i	A ,	(i.	∩ ™	G. L. D	∩⊠
25 C _1		G_1 1 1 1 1 1 1 1 1 1	∪⊠		
1: A <u>u</u> 2020, ■ n ! . i	ا القاداء القاداء المالية الم				A. i. 2020, n ⁱ
2: _ n C · 知 M K n M K n Z曲优) M M	ال القائد القائد القائد التقائد التقا			,	CUT PTIB :

D_I . _ | M A M _ I

No.	Туре	Name of R&D project on drugs (products)	Indications	R&D stages as at the end of the Reporting Period in the PRC	Stage of clinical trial as at the end of the Reporting Period in the PRC
1	Cn ⊿⊠	A-824	' i i i i i i i i i i i i i i i i i i i	C _l _l 📓 🖟	∩⊠
2	Cn .ı⊠	A a a a a a b i		C I I I I	n⊠
3	Cn .i⊠			= D	∩⊠
4	Cn _ı⊠	B ı⊠ _⊥ .i			∩⊠
5 6	Cn .I⊠		☑ _ . i i i	'	∩ ⊠

Management D_i . _i A A _i

No. Type	Name of R&D project on drugs (products) Indic	ations	R&D stages as at the end of the Reporting Period in the PRC	Stage of clinical trial as at the end of the Reporting Period in the PRC
7 Cn 8 n 8	, 📓 _I 📓 002 ' 1		- D A -	
9	(B 162 1)(2)		ا المار	ו בח ב בר ב בר ב ב בר ב ב בר ב בר ב בר ב
	ĺ		UB T B B 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
A		ii		

D_I , _ | M A M _ I


D. J., n J.,

D_1 , _1 \(\bar{\text{A}} \\ \alpha \\ \alpha

 Political
 Political

D_I , _I 📓 A 📓 _I


D_I , _I 🛮 A 🖺 _I




C. : B دید : ٍ ∑ي

Amount for the period	Amount for the corresponding period of last year	Period-on- period change (%)	Reasons
13,965	14,085	0.85	
6,216	5,599	11.02	
3,931	4,998	21.35	1
1,322	1,148	15.16	
1,204	849	41.81	2
428	547	21.76	3
1,461	1,450	0.77	
-2,379	1,079	120.55	4
827	496	266.75	5
	13,965 6,216 3,931 1,322 1,204 428 1,461 -2,379	for the corresponding period of last year 13,965 14,085 6,216 5,599 3,931 4,998 1,322 1,148 1,204 849 428 547 1,461 1,450 -2,379 1,079	for the corresponding period of last year (%) 13,965

D_I . _ | M A M _ |



D_1 , _1 🛮 A 🖺 _1



ि नैः गान	C.	:	В
-----------	----	---	---

		Principal	operations by s	segments	Beded as anded	
By segments	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
∩	9,952	3,754	62.28	7.97	3.79	■ 4.27
T M M T M T	2,639	1,309	50.40	47.18	49.21	0.68 [M _1
⊠ n ⊠ 」 (2)	1,359	1,130	16.82	6.85	4.68	■ 9.16 ■ J i i
		Principal	operations by	products		
Products	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
	1,767	278	84.26	2.19	4.51	86.0 ₪ L j ₪
Mg . Mg	422	119	71.89	59.94	71.10	■ 1.83
i	1,800	631	64.93	22.77	1.68	■ 7.52 ■ 1
Mg . Mg	755	48	93.63	38.35	16.94	■ 1.64
Mg .	1,248	484	61.20	9.49	20.22	■ 3.46 ■ J i i
Mg . ' i ∩ Mg 1 Mg Mg (247	20	91.74	41.03	0.42	■ 3.37
A M	452	330	27.11	32.97	31.29	⊠ 1.79 ⊠ ⊥ i i

Management
D_I . _I A A _I

Principal operations by geographical locations

By geographical locations	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
Cul ⊠ila	9,894	4,093	58.63	8.30	11.40	■ 7.32 i ¹
ال. ال. 🏿 💂	4,071	2,123	47.84	23.53	10.29	_l

Management D_I . _I A A _I

⊸.	. . •ı (1)	ኢ		٦	k	ኢኢ	* \	. . Pi	Pi		/∩ //	A.
	(1)		ፆ	□ l								

						- اا :أ كي	ı C.	: В
Name of subsidiary	Nature of business	Major products or services	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
⊠ ∪⊠ ⊠	∩⊠ ⊠	A 1 , . D.1 , _n@ D. 1 . 1 , _n@ D. 1 . 1 , _n	197	5,753	3,514	2,414	485	416
	∩⊠ ⊠ 1⊠	i ; BM , K.n. M . J. , M M M J . J. , M	440	5,176	2,770	2,825	441	369
120 120 22	∩⊠ ⊠ ⊠ ⊠ . ⊒i. ⊠ &D		/A	6,956	5,645	1,476	562	419
A M A M	∩⊠ ⊠	A D ,, B₪	510	2,626	1,864	599	64	61
: n 🛮 🗳			■ ■ į į	M		i i i		
_ a . ■j	ا ا اا ا	n Bı _	· į					


_	1	1						
			1	⊠ ı:	11 1 4	C. :	:	В

					·		
Name of subsidiary	Nature of business	Major products or services	•	Total assets	Net assets R	Revenue	Net profit
_∩⊠.∩⊠⊔ ı⊒ (<i>1)</i>)	⊠ ₁ <u>.</u> ⊠ .	543	5,536	3,708	110	448
Cn n	j a l	⊠ ∩ ⊠ ∟	50	2,528	1,728	686	41
1 📓1 📓 (1)	■ 8D ¹	_ [2] _ 	/A	2,745	2,302	504	40
1: ∩ ⊠⊠ _∩⊠ ⊠ . ;	I.∪⊠ ≀ ⊠ ⊒	_l 2 į	Mari in .	J į	טובי . ו	ا 2020	j'. L
2: n ■ Cn■	n . jm l . M			ا ا		.ı 🛮 .	■ .■

Management D_i . _i A A _i

				j: u	.ı С. :
Name of investee	Nature of business	Principal activities	Registered capital	Total Net assets assets R	Operatir Revenue prof
هي. ه∩ اــ	∩⊠ ⊠	∩⊠ ⊠l⊠ i i	100	307,273 84,008	203,765 4,80
- 		h h	n ()
A		50% - 1 100%	.I 	j _1⊠ U 1 ⊠ j ⊠ ∭	in ⊠Anji ianji . A ⊠ _r i i
. 2020 الـ 8 A هـر أ. بالر C C (B أ. و. بالر C C (B هـر			l, i _i i 51% i 	I_∩	in C i i i i i i i
. i . U ■ . ⊤i . i	j	i-11	ו ו ו ∭	. i i .	· ' 📓
				يًا: ال	.ı С. :
		Acquired	Net assets (as at the end of Reporting	Net profit (from date of acquisition/ merger up to the end of Reporting	Date o acquisition

D_I . _ | A B _ |



D_I . _I 🛮 A 🖺 _I

D_I , _I 🛮 A 🖺 _I

3. Potential Risks

D_I . _ | M A M _ |

. KNO A . D Ja, A

D_I . _ | A A _ .

- (2)
- (3)

D_| , _| \(\bar{\text{\tin}\text{\tetx{\text{\tetx{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\ti}\}\tittt{\text{\text{\text{\texi}\text{\texi}\text{\texi{\tex{\texi}\text{\texi}\text{\text{\texi}\titit{\texitit}}\\tittt{\ti}\text{\text{\text{\texi{\text{\texi}\text{\texi}\text{\texit{\t

(2) ∪ ॰ छातींछाँ छ ॰ नींना छ। ॰ ना । नाछाँना

4. Other Events

D_I . _I 🛮 A 🖺 _I




RESULTS AND DIVIDENDS



PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Sell back of "17 Fosun 01" Corporate Bond



DIRECTORS

Executive Directors

```
. Cn _i. (陳啟宇)( n )
. ■ ˌ■ . (姚方)( - n )
. . . _圖 . (吳以芳)( n )
```

Non-executive Directors

```
. K KM M (徐曉亮)
. . . . (龔平)
. M D . n. . (潘東輝)
```

Independent Non-executive Directors

Statutory

DII.

SUPERVISORS

```
.    』 (任倩) ( n
. C■    」. (曹根興)
. . 🛮 🔟 (管一民)
```

CHANGE OF INFORMATION OF DIRECTORS AND SUPERVISORS

```
■ ■ - . _ 」 B■ . ( :01761), ■ ■ '___

i i i i i
. . □ 」」, □ 」 , □ □ □ □ 」 , □ □ □ . □ . C □ □ , □ , □ , *(上海華誼集團股份有限公司)( ; :600623), □ □ □ □ , □ □ , □ □ , □ □ , □ □ , □ □ , □ □ . , 24_. 2020.
```

SHARE INCENTIVE SCHEMES

Gland Pharma Share Option Incentive Scheme

Participant	Date of Grant (dd-mm-yyyy)	Vesting Date (dd-mm-yyyy) ⁽¹⁾	Option share ⁽¹⁾	Exercise Period ⁽¹⁾	Outstanding options as at 1 January 2020	Adjusted during the Reporting Period ⁽²⁾	Exercise price per share ⁽³⁾	Forfeited or lapsed during the reporting period ⁽⁴⁾	Outstanding options as at 30 June 2020
		26-6-2020 31-3-2021 31-3-2022	40%	26-6-2020 26-6-2029 31-3-2021 26-6-2029 31-3-2022 26-6-2029					
	27-6-2019	31-3-2021 31-3-2022	30%	31-3-2021 26-6-2029 31-3-2022 26-6-2029	151,350	1,362,150	542	(20,000)	1,493,500
		31-3-2022	30%	31-3-2022 26-6-2029					

:

- (5) D. J. j , j , k ,

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES



Name of Shareholders	Nature of interest	Class of Shares	Number of Shares ⁽¹⁾	Shares in relevant class of Shares
' ' TU U ' ' TU U	В Т № В Т №	_n a A _n a	48,803,000 () ⁽²⁾ 938,095,290 () ⁽²⁾	8.84% 46.65%
	i i i	a' ∀ ∨a a' Y ∨a -	48,803,000 (;) ⁽²⁾ 938,095,290 (;) ⁽²⁾	8.84% 46.65%
		Br∪B Br. 4 _∪B Br. 1 _∪B	48,803,000 (·) ⁽²⁾ 938,095,290 (·) ⁽²⁾ 48,803,000 (·) ⁽²⁾	8.84% 46.65% 8.84%
	i i	⊠,¹ ~∪⊠ ⊠,¹ ∀~∪⊠ '	938,095,290 () ⁽²⁾ 48,803,000 () ⁽²⁾	46.65% 8.84%
	ii la i li la i B_la	ali A_nali A_nali	938,095,290 (,) ⁽²⁾ 114,075 (,)	46.65% 0.01%
B B U B 1 8 C .	i i -l ■ "	□ □ □ □ □ □ □ □ □ □	38,723,000 () 38,707,016 () 28,195,990 ()	7.02% 7.01% 5.11%
, .	1 1 - 1		==,:55,556()	5.1.1,0



DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES



Approximate


0.14%

782,000 (_)

Statutory

D_1 1 .

MODEL CODE FOR SECURITIES TRANSACTIONS



COMPLIANCE WITH THE CG CODE



REVIEW OF INTERIM RESULTS AND INTERIM REPORT BY THE AUDIT COMMITTEE



_∩M . ∩M . n C 25 A . . 2020





	ii	For the six month 2020 RMB'000 (Unaudited)	s ended 30 June 2019 B'000
REVENUE C .	5	13,965,179 (6,215,872)	14,085,146 (5,598,983)
- 1		7,749,307	8,486,163
,	6	180,429 (3,931,067) (1,322,239)	109,724 (4,998,448) (1,147,889)
	7	(1,204,425) (42,765) 603,622	(849,383) (21,918) 389,686
	8	(52,138) 96,436 (427,878)	(45,617) 86,650 (546,940)
		(46,558) 698,964	(25,933) 760,055
PROFIT BEFORE TAX	9	2,301,688	2,196,150
i	10	(392,081)	(376,521)
PROFIT FOR THE PERIOD		1,909,607	1,819,629
A : i i n m i i i - i "		1,714,710 194,897	1,516,120 303,509
		1,909,607	1,819,629
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT BM	12		
, <u>;</u> ;		RMB0.67 Yuan	B0.59 . ■
, ^f ^f ^J ^л П		RMB0.67 Yuan	B0.59 . ■



	For the six month 2020 RMB'000 (Unaudited)	s ended 30 June 2019 B'000 B <u>Q</u> <u>B</u>)
PROFIT FOR THE PERIOD	1,909,607	1,819,629
OTHER COMPREHENSIVE (LOSS)/INCOME		
	(255,609) 27,958	100,825 (30,026)
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods	(227,651)	70,799
	3,727 24	(26,819)
	3,751	(26,824)
	68,933	
Net other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods	72,684	(26,824)
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, NET OF TAX	(154,967)	43,975
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	1,754,640	1,863,604
A	1,660,547 94,093	1,544,923 318,681
	1,754,640	1,863,604



		30 June 2020 RMB'000 (Unaudited)	31 D 2019 B′000 (A ੍])
NON-CURRENT ASSETS			
. ⊠ ■ .	13	11,313,846	10,720,960
i'''' i''' i''' i'''' i'''''''''''''''		2,389,837	2,454,742
TI		9,093,050	9,013,990
		9,238,300	9,036,246
i i gigi		356,204	381,332
		21,712,444 60,945	20,491,557
		1,851,891	107,709 1,983,155
		236,457	196,095
i i i ■ · · · ■		1,300,703	1,273,605
,		57,553,677	55,659,391
CURRENT ASSETS			
i J		4,561,539	3,940,537
	14	5,271,488	4,607,722
		1,628,029	1,420,087
		992,812 354,915	456,651 445,103
D		9,750,416	9,533,268
		57.56,	
		22,559,199	20,403,368
CURRENT LIABILITIES	15	2,864,017	2,397,315
	. 5	6,116,649	5,376,193
~ i	16	12,404,601	8,560,202
· 💆 · 🍱 ːlːlːl		138,571	143,786
		527,652	503,683
		487,052	452,587
ैं छ र ं । छ सर्गर		22,538,542	17,433,766
NET CURRENT ASSETS	-	20,657	2,969,602
TOTAL ASSETS LESS CURRENT LIABILITIES		57,574,334	58,628,993

	_	30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A 1)
NON-CURRENT LIABILITIES	16	10.052.519	12 576 007
,	10	10,953,518 369,340	12,576,907 410,188
D		2,928,227	2,994,048
D		417,091	417,345
يلِد ۩ ١ م م		2,891,682	2,860,170
Ct la la tuli		215,655	223,009
_i -		17,775,513	19,481,667
Net assets		39,798,821	39,147,326
EQUITY Equity attributable to owners of the parent			
_∪ ⊠ ⊠ ¹ ⊠		2,562,899	2,562,899
<u></u>		30,419,792	29,268,280
		32,982,691	31,831,179
Non-controlling interests		6,816,130	7,316,147
Total equity		39,798,821	39,147,326

Chen Qiyu Wu Yifang







Attributable	to owners	of the	naront

	Share capital RMB'000	Share premium RMB'000	Fair value reserve RMB'000	Statutory surplus reserve RMB'000	Other reserve RMB'000	Exchange fluctuation reserve RMB'000	Retained profits RMB'000	Total RMB'000	Non- controlling interests RMB'000	Total equity RMB'000	
A 1 2020 (A 1)	2,562,899 —	11,385,162* —	(35,546)* —	2,523,799* —	899,356* —	(420,878)* —	14,916,387* 1,714,710	31,831,179 1,714,710	7,316,147 194,897	39,147,326 1,909,607	
. , , , , , , , , , , , , , , , , , , ,	_		3,819					3,819	(68)	3,751	
	_		96,891					96,891		96,89°	
	_					(154,873)		(154,873)	(100,736)	(255,609	
			100,710			(154,873)	1,714,710	1,660,547	94,093	1,754,640	
ار الساق المار المارة الما المارة المارة	_				159,607			159,607	(521,291)	(361,68	
					(784) (2,433)			(784) (2,433)	62 —	(72 (2,43	
					_			_	56	5	
) 1 1 - 11	-								24,495	24,49	
. 1									(241,721) 162,645	(241,72 162,64	
	_				5,346			5,346	(18,356)	(13,01	
وس و ۲۰۲۲ برهب ۱۲۷ وس ۱۲۰۲۳ وس وس	_				329,734			329,734		329,73	
(11) _ ■ 1919	_						(1,000,505)	(1,000,505)		(1,000,50	
			107,320				(107,320)				
1 ₁ 30 ₂ . 2020 ₁	2,562,899	11,385,162*	172,484*	2,523,799*	1,390,826*	(575,751)*	15,523,272*	32,982,691	6,816,130	39,798,82	
* ^ a .	j U	ا_ ا أ	B3	30,419,792,00	00 (31 D	2019:	B29,268,28	۱ _. (80,000	1_ \ j	⊠ i i	



				A J. 🛮 1	i	n 🛮 i					
	B'000 ■ 1 ■ P'000	_∩⊠ .i B′000	⊠ . ∩⊠ B′000	, ⊠_l ⊠. B′000	i i i _{ı.} B′000	, ● n B′000	∩M . 1 M _ i i B'000	i i j B′0000	B′0∳0	- - "-1. - ¹ B′0000	. i j B′0000
2019 (A ,) 1	2,563,061	11,386,711*	(1,711)	30,105*	2,374,998*	(701,196)*	(293,315)*	12,562,197* 1,516,120	27,920,850 1,516,120		33,535,827 1,819,629
ur pali				(26,838)					(26,838)	14	(26,824)
<u>M</u> M				(30,026)					(30,026)		(30,026)
j 1							85,667		85,667	15,158	100,825
; ; l				(56,864)			85,667	1,516,120	1,544,923	318,681	1,863,604
j 188∪ V j	(162)	(1,549)	1,711			(81,915)			(81,915)	(9,499)	(91,414)
الأن الأرا الا إلا.	(102)	(1,545)	1,711							23,284	23,284
]] i⊠ i⊠ ∭a					(4.000)	1,129 (2,214)		4.000	1,129 (2,214)	(1,129)	(2,214)
8 18 1 × 1887 7 8 × 1887					(1,000) (314)			1,000 314		(662)	(662)
y⊠ ∪ '										31,290	31,290
, ™ ™ , ™ ™ , ™ ™										(170,553)	(170,553)
17 B° B ₁										61,867	61,867
18						39,361			39,361	(86,121)	(46,760)
rmg 88 117 1280 881 1810 281 1810 281 1810 1810 18						67,968		(818,627)	67,968 (818,627)	6,876	74,844 (818,627)
, 30 <u>,</u> 2019 <u>@</u> 🛮 i)	2,562,899	11,385,162*		(26,759)*	2,373,684*	(676,867)*	(207,648)*	13,261,004*	28,671,475	5,789,011	34,460,486







Can a a a a a a a a a a a a a a a a a a	2020 RMB'000 (Unaudited) 1,928,625 (467,328) 1,461,297	2019 B'000 1,849,335 (399,147) 1,450,188 (2,040,985) (133,162)
CASH FLOWS FROM INVESTING ACTIVITIES	(Unaudited) 1,928,625 (467,328) 1,461,297	1,849,335 (399,147) 1,450,188
CASH FLOWS FROM INVESTING ACTIVITIES	1,928,625 (467,328) 1,461,297 (1,904,148)	1,849,335 (399,147) 1,450,188 (2,040,985)
CASH FLOWS FROM INVESTING ACTIVITIES	(467,328) 1,461,297 (1,904,148)	(399,147)
CASH FLOWS FROM INVESTING ACTIVITIES	1,461,297 (1,904,148)	1,450,188
CASH FLOWS FROM INVESTING ACTIVITIES	(1,904,148)	(2,040,985)
ه أ ها '' ا '' ا " ا " ا ا ها ا		
n -	(8,400)	(133.102)
_1	(192,431)	(174,524)
	(435,607)	(174,324)
D_I MADA NI _I, _I MADA MA	151,917	35,418
	474,449	642,245
	-	2,296
Dil i M M	67,961	41,866
D_1	_	1,039
	18,718	20,053
	1,708	
, ™ ™ ™ ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '		
	5,439	26,015
	50,228	
1		
	(570,138)	570,562
• n -i	(38,629)	39,801
[™] ■ ∪	(2,378,933)	(1,078,659)



1. CORPORATE AND GROUP INFORMATION




2. BASIS OF PREPARATION

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES



30_ 2020 i i i

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)



, _| M _ _ j 30 June 2020

4. OPERATING SEGMENT INFORMATION





4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2020 (unaudited)

	Pharmaceutical manufacturing and R&D RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharmaceutical distribution and retail RMB'000	Other business operations RMB'000	Adjustments and Eliminations RMB'000	Total RMB'000
Segment revenue:	0.052.005	2 620 007	4 350 047		45 470		42.065.470
	9,952,096 48,294	2,638,887 46,610	1,359,017 4,700		15,179 8,270	(107,874)	13,965,179 —
<u>■</u> .	10,000,390	2,685,497	1,363,717	_	23,449	(107,874)	13,965,179
Segment results*	1,115,513	509,746	31,373		(4,289)	(19,026)	1,633,317
n u	135,673	10,551	16,910		16,579	_	179,713
^ì n . ⊠_ı	157,704	14,210	3,393		275,233	30	450,570
`` _ 	56,129	10,345	17,531		185	(5,291)	78,899
ra i i	(51,353) 27,605	(14,125) (55,433)	(17,409) (6,267)		(5,587) (22,062)	26,170 —	(62,304) (56,157)
પ ા ૈં≣ા :	(45.744)				(0.4.4)		(45 550)
A i mi	(45,744) 32,681	 24,021	— (31,134)	— 724,041	(814) (50,645)		(46,558) 698,964
L L, L 0 🕍 🗠							
M [1] [M]							171,305
ļ⊠, ⊠ ¹ , _1⊠ ⊠, ⊠ ¹ , _1							(365,574) (380,487)
	1.428.208	499,315	14,397	724,041	208,600	1,883	2,301,688
_!	(313,433)	(65,625)	(12,784)		(239)		(392,081)
j j I U T	1,114,775	433,690	1,613	724,041	208,361	1,883	1,909,607
Segment assets:	41,047,332	8,262,367	9,812,781	13,877,770	4,251,314	(1,683,155)	75,568,409
b 1, 1	349,474	_	_	_	6,730	_	356,204
	2,248,581	1,102,609	1,624,283	13,877,770	2,859,201		21,712,444 4,544,467
™ i							80,112,876
Segment liabilities:	18,654,179	1,937,780	2,229,824		386,141	(9,370,028)	13,837,896
j 💆 , 💆 Tr ^f T							26,476,159
<u>f</u>							40,314,055
Other segment information:							
	590,999	96,170	133,901		15,197		836,267
	(22.254)	10.505	-2.25		22.040		44.040
	(32,251) 1,309,447	49,686 97,984	2,365 356,886		22,048 47,953		41,848 1,812,270
* ; '	· ì	ì	, 11.	ار ال	الداد 🖪 ,	.1 📓	■ n ■
-	_ _ 	, 'B B L L . L B .	ı). '' i ^{n _i}	■ l · ■ · i	<u> </u>		اً الـ الـ ا



4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2019 (unaudited)

	∩⊠ ⊠	B,000	⊠ n ⊠ i B′000	B,0000 □	B,000	A .}- i ⊠ i Bi0000	B′0 <u>0</u> 0
Segment revenue:	10,814,123 8,421	1,792,865 19,401	1,458,512 1,876		19,646 20,674	(50,372)	14,085,146
□ . □ .	10,822,544	1,812,266	1,460,388		40,320	(50,372)	14,085,146
Segment results*	1,204,721 75,540 281,499 50,628 (56,712) (15,616)	291,795 13,034 (3,481) 16,153 (9,467) (22,095)	168,982 3,681 (748) 21,874 (12,032) (15,446)	7,274	10,328 3,326 2,679 216 (6,320) 1,121	(19,887) (1,236) 29,102	1,655,939 95,581 287,223 87,635 (55,429) (52,036)
	(25,565) 37,529	477 (25,330)	(13,655)	774,939	(845) (13,428)		(25,933) 760,055
						-	115,621 (491,511) (180,995)
	1,552,024 (319,655)	261,086 (30,673)	152,656 (51,774)	782,213	(2,923) (258)	7,979	2,196,150 (402,360) 25,839
L O L	1,232,369	230,413	100,882	782,213	(3,181)	7,979	1,819,629
Segment assets:	36,425,494	6,874,258	10,781,464	12,429,996	4,362,843	(1,490,584)	69,383,471
	399,018 2,153,707	12,808 948,143	3,232,275	12,429,996	9,134 3,085,411	-	420,960 21,849,532 4,249,250
⊠ a i i							73,632,721
Segment liabilities: ፬ 🔊 🖳 ալ ւ 🔊 ուլո	15,346,659	1,505,277	1,698,142		281,002	(8,590,276)	10,240,804 28,931,431
2 1							39,172,235
Other segment information: D	502,504	85,220	133,338		19,190		740,252
	2,435 1,016,436	19,425 85,165	6,493 160,766		(2,198) 95,489		26,155 1,357,856
* ; ;	. į .	ı l	, ייבו. 🛭	ا ، ا ا	, 📓 _l _l 🧸	lı 📓	■ ∩ ■
** C 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		, I⊠	, j, j, j	■I ■ ■ . j	2 _1 (2)	■ ■	ן דריין



5. REVENUE

	For the six month	ns ended 30 June
	2020	2019
	RMB'000	B'000
	(Unaudited)	(i 🖳 🔟
	13,951,418	14,066,560
. , n .		
, ™ _ '	13,761	18,586
	13,965,179	14,085,146





5. **REVENUE** (Continued)

For the six months ended 30 June 2019 (unaudited)

i	∩⊠ ≌	B,000	B'000	B,000	B'000
Types of goods or services					
	10,564,090 238,771 11,182	1,671,542 111,402 9,921	27,181 1,430,327	2,144	12,262,813 1,782,644 21,103
■ . ■ In .	10,814,043	1,792,865	1,457,508	2,144	14,066,560
Geographical markets					
`	8,288,825 2,525,218	1,024,242 768,623	1,457,508	406 1,738	10,770,981 3,295,579
a. a. in.	10,814,043	1,792,865	1,457,508	2,144	14,066,560
Timing of revenue recognition					
	10,575,272 128,209 110,562	1,681,463 41,595 69,807	27,181 1,430,327	2,144	12,283,916 1,602,275 180,369
■ . ■ in . i i i i	10,814,043	1,792,865	1,457,508	2,144	14,066,560



6. OTHER INCOME

	For the six months ended 30 June	
	2020	2019
	RMB'000	B'000
	(Unaudited)	(ا _ب 🗷 🕰
· i T i mal mar u v u u u u u u u u u u u u u u u u u	20,391	17,523
	158,367	92,104
J _ n	1,671	97
	180,429	109,724
<u></u>		

7. OTHER GAINS

	For the six montl	hs ended 30 June
	2020	2019
	RMB'000	B'000
	(Unaudited)	(I 🖳 🖺
mada a a a a a a a a a a a a a a a a a a	87,209	27,528
ا أ ا `` القاه أو أو أو القالة القاه القالة الق	439,102	327,405
	_	2,186
, ₽ _i n	77,311	32,567
	603,622	389,686

8. FINANCE COSTS

	For the six months ended 30 June		
	2020	2019	
	RMB'000	B'000	
	(Unaudited)	(ہے 📓 🕰	
		L	
ं 🏿 🔻 प्र ा. १ । १ । १ । १ । १ । १ । १ । १ । १ । १	425,687	543,161	
ا الله الله الله الله الله الله الله ال	12,188	12,355	
	(9,997)	(8,576)	
		_	
i i 'i	427,878	546,940	



9. PROFIT BEFORE TAX


U	, '	_l	■ _ ■ _ i	ı 🛮 🗗	∩⊠1, /(_l_l,):

	For the six months ended 30 June		
	2020	2019	
	RMB'000	B'000	
	(Unaudited)	(اِ الله الكي	
С ; д ; д !	4,932,900	4,263,438	
	1,282,972	1,335,545	
		_	
_	2,468,297	1,952,209	
	=,133,=37	.,552,255	
D	66,453	134,290	
A 👼 i 🐪 :		_	
D_I	83,795	67,904	
	39,516	46,956	
		_	
	2,658,061	2,201,359	
		_	
C	1,167,594	816,188	
· : &D , * · · · · · · · · · · · · · · · · · ·	46,028	12,128	
		_	
	1,121,566	804,060	
		_	
	12,963	10,981	
	490,945	458,599	
D M 1 1/1-1- M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	91,076	74,916	
	254,247	206,737	
	(917)	4,237	
	42,765	21,918	
	(439,102)	(327,405)	
, –I ∩Ma. Ma_I, ₁	(69,551)	(6,028)	
	(1,621)	(18,465)	
	יו או איי איי איי איי איי איי איי איי אי	n⊠ , į	





10. INCOME TAX



	For the six month	ns ended 30 June
	2020	2019
	RMB'000	B'000
	(Unaudited)	(إ 📓 🧕
C	467,327	464,045
D	(75,246)	(87,524)
⊠	392,081	376,521

11. DIVIDENDS




nsed Consolidation of the cons

12. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT





13. PROPERTY, PLANT AND EQUIPMENT



14. TRADE AND BILLS RECEIVABLES

									30) June	31 D
										2020	2019
									RM	IB'000	B'000
									(Unau	dited)	(A,I)
											ì
	_ 🛮 ।								5,08	80,545	4,367,600
Вл	_ 🛮 ।								19	00,943	240,122
									5,27	1,488	4,607,722
П U	_ _ - 	i il i	_l⊠ \ _l. - ⊠ _l į	⊠ı ∩ ĺ	ί, υTυ į	a	ì	, j	'n	⊠ j . į	. 🛭 🖺



14. TRADE AND BILLS RECEIVABLES (Continued)

	⊠	⊠ı ⊠ ,_I⊠
	30 June	31 D
	2020	2019
	RMB'000	B'000
	(Unaudited)	(Aįı)
_in_i 1	4,999,855	4,302,722
1 1 2 📓	144,630	111,346
2 ¹ 3 ■	67,601	61,584
_ i 3 ■	125,446	114,549
<u> </u>		
	5,337,532	4,590,201
, : <u>=</u>	(256,987)	(222,601)
<u> </u>		
	5,080,545	4,367,600
A 📓 30, 2020, 📓 🔟 🕍 📓 . B5,300,000 (2019: B8,146,000)	i i	□ _l, ·

15.

TRADE AND BILLS PAYABLES		
	30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A j
■ ■ ■ B ₁ ■ ■	2,566,965 297,052	2,152,747 244,568
	2,864,017	2,397,315
	30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A 1
	2,516,937 34,054 9,155 6,819 2,566,965	2,105,194 36,473 3,082 7,998



16. INTEREST-BEARING BANK AND OTHER BORROWINGS

		30 June 2020 RMB'000 (Unaudited)	31 D 2019 B′000 (A)
B⊠	(1)	486,008 15,096,396	344,186 13,762,714
	-	15,582,404	14,106,900
_ n -	(2) (3)	899,616 6,876,099	7,030,209
<u>i</u>		23,358,119	21,137,109
		(12,404,601)	(8,560,202)
		10,953,518	12,576,907
	Ţ 1111) 1 ₪	11 :	
		30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A ,)
□ □ :		12,404,601 7,833,867 2,633,443 486,208	8,560,202 6,860,077 5,395,435 321,395
الله الله الله الله الله الله الله الله	-	23,358,119 (12,404,601)	21,137,109
i i		10,953,518	12,576,907



16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

(1) Bank loans ∩ ■ | ■ ■ _| ■ ■ _| . _|. 0.3000% 6.2000% (31 D 2019: 0.7500% 7.5000%) ■ . . (2) Super Short-term Commercial Paper B600,000,000, ∩_i∩ ■ _i , ■ 2.50% B300,000,000, ∩_i∩ ■ _i i i (3) Corporate bonds B1,300,000,000, ∩_i∩ ■ ● 30 2018, ∩ C ■ ... ■ ... □



17. BUSINESS COMBINATION



16,150



17. BUSINESS COMBINATION (Continued)

A B	j j j . ■	
		B'000
		(<u>j.</u> 📓 🔍
C⊠n	ı ⊠ [*] ı ⊠ı	(10,970)
C⊠ n ⊠	□ n i	14,529
		3,559
	. 🖳 📓 n	(11,959)
		(8,400)

18. COMMITMENTS

	30 June 2020 RMB'000 (Unaudited)	31 D 2019 B'000 (A _ l _)
	2,316,640 880,140 253,149	2,191,767 929,930 273,236
i i ' i i i i i i i i i i i i i i i i i	4,434,832	4,285,335
	7,884,761	7,680,268



19. RELATED PARTY TRANSACTIONS

(a) Sales of pharmaceutical products and services

	For the six months ended 30 June	
	2020	2019
	RMB'000	B'000
	(Unaudited)	(_ا 🏿 🖳
	_	
_ı ∩M . C ., . M M (4 & 6 & 15)	1,395,932	1,567,956
C n a a . , l a . i . l . C ., i . a . l . l . a . l (1 & 4 & 16)	188,335	205,246
C n	98,576	216
ب إلى أن الله الله الله الله الله الله الله الل	92,686	49,757
	68,855	42,836
الأرأم, D. D. D. إلى الأرام, D. D. D. إلى الأرام,	7,036	32,492
	4,315	
A	4,030	3,256
nm, nm_lD_mmnm C ., (1 & 4)	2,555	1,453
اـــر 📓 . ماها 📓 . الـــر C ., الــر	1,777	22
nM,nM_1K_1, M1Mn,D,C,(2&4&17)	1,612	4,702
_■■ B ₋₁ _1■, .(1&4)	1,262	
$\square \square \square \square \square \square \square$, .($1 \& 4$) , $\square \square \square \square \square \square$, .($1 \& 4 \& 6$) , $\square \square \square \square \square \square$, $\square \square \square$, $\square \square \square$, $\square \square \square$, $\square \square$, $\square \square$, $\square \square$, \square ,		
(18486)	737	1,575
(2 & 4)	406	148
, . L⊠ _l	42	
	16	
	16	17
\mathcal{L}	14	12
∩ MIK_I.	13	60
_் பெ பி பி வி பி	3	
	_	17
_ ♠ A ⊿■ _ ⊥ & n ¹. C .,₁ . (1&4)	_	1
	4 000 040	4 000 755
	1,868,218	1,909,766



Six months ended 30 June

Six months ended 30 June

19. RELATED PARTY TRANSACTIONS (Continued)

(b) Purchase of pharmaceutical products and services

	Six months chaca so sanc	
	2020	2019
	RMB'000	B'000
	(Unaudited)	(. 🗷 🕰
		1
-1 n . C .,	128,644	125,937
, . , , , , , , , , , , , , , , , , , ,	96,578	1,156
Ch 1 1	87,769	8,899
C n a a a 1 1 1 C ., a a . (1 & 4 & 16)	2,266	410
$- $ \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc	1,071	1,164
An n n n n n n n l l l C ., l (1 & 4)	1,007	2,126
An \square n \square	907	85
_An	510	3,352
	33	
	23	
■■ B ₁ 1■, .(¹ 1 & 4)	_	1,318
C C(_ n.) n n n. C., . (1&4&1)	_	1,228
	318,808	145,675

(c) Leasing and property management services

	2020	2019
	RMB'000	B'000
As lessor	(Unaudited)	(📜 🗷 🔍
, . ¸ı B_ıı, _ı⊠ ∩ ı, C .,ı¸ .(2 & 5)	6,106	5,310
, . , Marail Marail (3 % 5 % 12 % 16)	3,529	7,895
_n⊠, n⊠_iK_i, ¹ ₪ _ ¹ ₪ _ ¹ n ı , C .,ı¸ . (1 & 5)	733	
_∩Ma, ∩Ma_nK_1, Ma _nMa n n . D n	578	325
.D, [⊠ ⊠ ⊠ , (_∩⊠, h⊠),C¹.,, . (5 & 7)	471	454
	413	131
(2 & 5)	216	
, , , ,	145	86
_ื่ ฒ ู้ Cบก , ี่ฒ ¬ขา บ <u>ต</u> า(1 % 2)	65	
	_	264
•		
	12,256	14,465



(d)

19. RELATED PARTY TRANSACTIONS (Continued)

(c) Leasing and property management services (Continued)

As lessee	Six months en 2020 RMB'000 (Unaudited)	nded 30 June 2019 B'000
, , , , , , , , (3 & 5 & 13 & 16) Dna a ja a	2,952 117 43 —	5,477 114 41 2,500
	3,112	8,132
Property management services	Six months en 2020 RMB'000 (Unaudited)	2019 B'000
, . Mai Mari Mari (3 & 5 & 14 & 16)	6,904	6,651
Loans from/to a related parties		
n C	i - 1	i i ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Maximum daily outstanding balance of deposits in Fosun Finance	Six months er 2020 RMB'000 (Unaudited)	nded 30 June 2019 B'000

& 16)

979,619

574,422

, . . , . | C | | | | | | (



19. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

	30 June	31 D
	2020	2019
	RMB'000	B'000
A loan from a related party	(Unaudited)	(A ,)
, ,	52,274	38,779
, , , , , , , , , , , , , , , , , ,	- 🖬 t 📓	B10,884,000 📓 📓
	30 June	31 D
	2020	2019
	RMB'000	B'000
Loans to related parties	(Unaudited)	(A _i)
園 ' つ. (園園) (1.2.16)	10,884	10,566
■ . ' . n.ı (, ■ _ ■ .) ı.ı.ı (1 & 16) ,, B.ııı	188,840	188,840
- 1 Dai , a 11 1 , C , 1 . (2 \(\delta\) 10	100,040	100,040
	199,724	199,406

(e) Interest income from/to related parties

	Six months ended 30 June	
	2020	2019
	RMB'000	B'000
Interest income	(Unaudited)	(ا 🗷 🕰
		_
, B.J., (2 & 16)	4,706	2,002
, , , , , , , , , , , , , , , , , , ,	3,358	1,845
, ,	160	154
	8,224	4,001



19. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/to related parties (Continued)



- (1) n **a a a** i
- (2) n **a** , _ i , _ i . .

- (6) ∩ **a** . _ı **a** . . .

- (9) n **a** n **a a** 1 n . .




19. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/to related parties (Continued)



(f) Compensation of key management personnel of the Group

	Six months ended 30 June	
	2020	2019
	RMB'000	B'000
	(Unaudited)	(<u>I</u> 📓 🖳
⊠ 1⊠, .	50,051	25,416
	15,410	12,417
٦ ١ ' ٦٠ ' ٦	243	501
	65,704	38,334






19. RELATED PARTY TRANSACTIONS (Continued)

(g) Outstanding balances with related parties (Continued)






20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)




Unobservable inputs for Level 3 assets





20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Unobservable inputs for Level 3 liabilities (Continued)



Fair value hierarchy



Fair value measurement using			
Quoted prices	Significant	Significant	
in active	observable	unobservable	
markets	inputs	inputs	
(Level 1)	(Level 2)	(Level 3)	Total
RMB'000	RMB'000	RMB'000	RMB'000
566 1,097,737 —	849 52,959 354,915	59,530 1,694,007 —	60,945 2,844,703 354,915
1,098,303	408,723	1,753,537	3,260,563

_ 31	201 ⊥)

· i □ i □ i □ i □ i □ i □ i □ i □ i □ i	, ⊠_1 圖. ■ . 1 _1_1	i i	B,000 <u>™</u>
1,554 561,348	52,909 52,734 445,103	53,246 1,825,724	107,709 2,439,806 445,103
562,902	550,746	1,878,970	2,992,618



Equity

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)



	investments
	Designated at
Financial assets	fair value
at fair value	through other
through profit	comprehensive
and loss	income
RMB'000	RMB'000
(Unaudited)	(Unaudited)

A [1] [2020] [202	1,825,724 118,774 — 68,397 (321,675) 2,787	53,246 — 6,284 — — —
A 🛮 30, 2020	1,694,007	59,530

Λ	j 🗐 🗐 .	A .	ا ا	13I, _n	1 11 :
h	h	<i>30</i> 🛮	201		

		B,000 B,000 B,000
A 📓 1 🔊 . 📓 2019	2,155,293 231,452	82,301
	446.220	(29,271)
A , 1.1 D.1 , 8	116,220 (332,911)	
	3,116	(340)
■ 1 12 i	(386,601)	
A ■ 30 2019	1,786,569	52,690



20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)



	Quoted prices in active markets (Level 1) RMB'000	Fair value measi Significant observable inputs (Level 2) RMB'000	urement using Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
. בוני ₪ ב יו ה	_	_	2,643,984	2,643,984
31 201 🚅)				
	(, a l a . a . i . i i	i	B′000
			209,286 2,608,958	209,286 2,608,958
			2,818,244	2,818,244
j	3 . ı, j . 	п :	Six months en 2020 RMB'000 (Unaudited)	nded 30 June 201 B'00 <u>(</u>
□ 1 □ . □ - □			2,818,244 35,026 (209,286)	2,913,87 46,70



21. CONTINGENT LIABILITIES

22. EVENTS AFTER THE REPORTING PERIOD

23. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

```
A _∩2 ( ),
A_n n ()
                                                                                                                                               A 🛮 🗎 🖺 , i
                                                                                                                                             C In A I
A. | | | |
                                                                                                                                            n ■ D<sub>-l</sub> i
В 🛮 ,
                                                                                                                                               n, ⊠i .ı_ı B⊠ıı
B 📓 1
                                                                                                                                                  В 📓 ,
                                                                                                                                                B_{\underline{\mathbf{A}}} \cdot \underline{\mathsf{I}} \cdot \underline{\mathsf{I}} \quad , \, \underline{\mathbf{M}} \qquad \quad \, \underline{\mathsf{M}} \quad \quad \underline{\mathsf{I}} \quad \quad \underline{\mathsf{M}} \cdot \underline{\mathsf{I}} \quad \cdot \quad \underline{\mathsf{M}} \cdot \underline{\mathsf{I}} \quad . \quad 
                                                                                                                                                 C , A , A , A , i
CA A
                                                                                                                                                C C
                                                                                                                                                 C. i I. I.
  1
                                                                                                                                               CUM I MIU
                                                                                                                                                  C C (B JILI. )
                                                                                                                                                 C C NM M . . .
```

```
C_ C,
D_I ()
       _ı () n C ■
       B DA
       _ - 1
- C - ii
      ⊿. ■ □
' ' 1 U U
       ∩ II - . _I <u>I</u>II , .
, , ! =1, ,
       , . ■」■ ' 」. '」」 (復星國際控股有限公司), ก」ก 」 ก | ■ 85.29% ■ i i i
```

Definitions

```
- M , .j_l _iM,
         TIT VM 🛒
          _∩⊠ ()
         u () _∪⊠
_∪⊠ ∪ । ()
          □ ∩ C□ □ □
□ n C□ □ □
         . n . 📲
         in . . , . | ■ | i . . . i ■
         . . . . . .
. . " , $
         ا ا الحال
i - 1-1 , . ,
         . , ∩ l⊠ .! .
         _ 3
_ = = ,
         ۵ ا ا ا ا ا ا ا ا ا ا ا ا ا ا
         1 C
         Ą
         U mail mai = 1 ∪ mai - 1 ⋅ mai
2
۔ وور
         ,₽ , - -|-|¤|-|-
         С,
```

```
ור ודודט
                                                                                                            ו וודט ט ווי ט
                                                                                                                U ' I'
      C, Cn_I
                                                                                                               i C B B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I B A I 
                                                                                                                     . 🛮 🗆 🗎
                                                                                                                    ■ n ■ n
    &D,
                                                                                                            n 6- n ... 1, ■ 2020 30, 2020
   ا ۔ ا
                                                                                                                       ا . ا. ⊠ا را لا ا
                                                                                                            ¬ C,
                                                                                                             ,
                                                                                                               _UM . UMI 131 .
in C
                                                                                                            ↑ _ ' _ 1 _ 1 _ ↑ _ ↑ _ ↑ □ ↑ □ ↑ □ ↑ * (《上海證券交易所股票上市規則》)
K.i. 🖺 _i🖺,
 _∪⊠ ∪ ।
                                                                                                             _n Ballon Ballon C Ballon Bal
 _∩⊠
                                                                                                        _n n _ i ⊿ n⊠.,
                                                                                                            _I NM ,
                                                                                                               _| | | |
                                                                                                                                                                                                                                                                                                                          : 01696) 🛭 🗳
                                                                                                         _ _ _ _ _ _ _
```

_ 1

Definitions

```
n_ 」C 」 n C ■
    _ _ C _i ,
                                                                                                                             ا ا⊠ ا ا
, DA , .... 🖳
                                                                                                                           الها الها ١٠
                                                                                                                              ı C ,
İl
                                                                                                                             \begin{bmatrix} \mathbf{a} & \mathbf{b} ```